Profil PT Kalbe Genexine Biologics (KGBio)

Profil Perusahaan / Lembaga - PT. Kalbe Genexine Biologics (KGBio)
Deskripsi Perusahaan / Kelembagaan

PT. Kalbe Genexine Biologics (KGbio) merupakan salah satu anak usaha dari perusahaan farmasi PT Kalbe Farma Tbk (Kalbe) dengan Kepemilikan Kalbe mayoritas sekitar 60%, sisanya dipegang oleh Genexine dan General Atlantic. KGBio adalah perusahaan joint-venture antara Kalbe Farma dengan perusahaan bioteknologi uji klinik Korea Selatan bernama Genexine. Sementara itu, General Atlantic merupakan  perusahaan growth equity firm global yang menyediakan modal dan dukungan strategis untuk perusahaan yang sedang berkembang.

KGbio is a clinical-stage biotechnology company established in 2016, focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals.

Platforms of interest include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).